pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
JAK · news · pharmadog
← back to JAK
News · JAK
24
stories
9h
Roivant, the 'inveterate drug hunters', enters commercial era with Lisraya
biospace
7d
6 immunology targets to sustain a mammoth I&I market
biospace
11d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
18d
North Immunology goes public via reverse merger as eczema drug heads toward clinic
fiercebiotech
27d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
Aug 28, 26
FDA green lights Priovant drug for rare skin disease
biopharma dive
Aug 28, 26
Priovant nabs first FDA approval for targeted tablet in dermatomyositis
biospace
Aug 27, 26
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults
fda press
Jul 30, 26
New funding, new jobs: 4 biotechs hiring after series B raises
biospace
Jul 29, 26
Incyte cuts early-stage cancer drug to focus on next-gen programs
biospace
Jul 28, 26
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
Jul 27, 26
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
Jul 16, 26
Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial
fiercebiotech
Jul 13, 26
Q32 bounces back to claim study success for alopecia drug
biopharma dive
Jun 18, 26
Biogen adds more immune drugs in $1B buyout of secretive startup RayThera
biopharma dive
Jun 15, 26
Lilly scores early positive data for new JAK drug
biopharma dive
Jun 8, 26
Incyte to buy blood disorder drug in possibly $2B deal
biopharma dive
May 10, 26
Five Under 5: Top Oncology Videos for the Week of 5/3
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
Apr 28, 26
Incyte claims double Phase 3 win in vitiligo, will file for approval
endpoints
Apr 27, 26
Lilly to buy startup Ajax in bid for a better JAK drug
biopharma dive
Apr 27, 26
STAT+: Astellas retries XLMTM gene therapy after deaths
stat
Apr 27, 26
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitor
endpoints
Dec 22, 25
Fierce Biotech Fundraising Tracker '26: TriGemX tacks on $94M; AnaCardio adds $71M
fiercebiotech
